To suppresses the oncogenic function of ERBB3 (also known as HER3), which is another catalytically defective RPTK, an anti-ERBB3 antibody was developed and is currently undergoing clinical trials as an anti-cancer drug [37]. The gene discussed is ERBB3; the disease is cancer.